Frankfurter Strasse 250
+49 6151 72 0
The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the US and Canada, has 19,000 employees and 72 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery.
Merck KGaA of Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials – and generated sales of € 11.3 billion in 2014. Around 50,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges.
Merck KGaA, Darmstadt, Germany is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day.
Merck KGaA, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Merck offers more than a complete range of high quality microbiology testing solutions for the pharmaceutical, cosmetics, municipal water, beverages and food industries.
It’s a comprehensive approach providing regulatory expertise, substantial service, and trust. For that one invaluable result: safe products.
It’s a time issue. A cost issue. And most important, it’s a risk issue. What’s required to cover all these issues is a vision. A vision for a safer future. That’s why we offer you a complete solution to help you stay on the safe side: with high-quality products, with excellent service, and with professional expertise, Merck Millipore provides more safety than meets the eye.
Let’s take a closer look: most contaminants are invisible to the naked eye. Although single micro-organisms (as well as those carried on particles) are fairly small, they pose a severe threat to the safety of products and brands: every year, several hundred products have to be recalled, resulting in financial and image losses.
At Merck Millipore, we believe that the solution to this problem is not only simple but also cost-efficient: with our complete portfolio for environmental monitoring, covering particle counting, active and passive air monitoring as well as surface and personnel monitoring solutions. The relatively low costs of monitoring result in improved quality and increased safety – and in the reduction of overall expenses.
To keep expenses low in the long term, Merck Millipore offers a comprehensive range of high quality monitoring and testing solutions that help you keep your facilities safe, from less critical to highly critical clean rooms and isolators. With our monitoring solutions you can conveniently check surfaces, equipment, and air quality for contaminants – getting answers rapidly and reliably. Since our products have been developed in close cooperation with users and authorities, they are tailored to the customers’ needs and follow international guidelines for critical and controlled environments, such as EU cGMP, USP, or FDA Aseptic Guidance. What’s more: as a one-stop supplier, we also offer a wide range of services, including IQ/OQ maintenance, calibration, product validation, and application.
Erbitux; Rebif; Gonal-f; Pergoveris; Luveris; Ovitrelle; Crinone; Cetrotide; Saizen; Euthyrox; Glucophage; Seven Seas; Easypod; Nasivin; Sangobion.
(2/2) @KaiBeckmann commented on the #MoU with @we_hspectrum: â€śWe are looking forward to a #partnership with Taiwanese entrepreneurs through the #InnovationLab to create more #breakthroughs for #healthcare plus #technology applications that go beyond what #Merck is doing today.â€ť pic.twitter.com/U1FvMCag4t— Merck (@merckgroup) December 18, 2018
(1/2) We signed a #MoU with @we_hspectrum (part of #YonglinHealthcareFoundation under #Foxconn) in #Taiwan to establish an #InnovationLab together. Topics are '#Biosensing & Interfaces', 'Liquid #Biopsy', 'Patient-centric Solutions' and '#PrecisionMedicine'. pic.twitter.com/CE18rkyuXM— Merck (@merckgroup) December 18, 2018